Anti-VEGF agents are considered to have equivalent efficacy and safety profiles in AMD treatment. These agents have demonstrated improved visual and anatomic outcomes compared with other therapies. However, consensus has not been reached regarding the ideal treatment intervals with anti-VEGF agents.
On January 28, 2022, the FDA approved the first bispecific ophthalmologic antibody, faricimab, for the treatment of AMD. Recent studies have shown that faricimab may potentially extend the interval time between treatments.
Learn more about the use of antiangiogenic agents for management of wet AMD.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: F. Ryan Prall. Fast Five Quiz: Exudative (Wet) Age-Related Macular Degeneration (AMD) - Medscape - Mar 31, 2022.